EFFICACY OF TELMISARTAN GROUP IN PATIENTS ISCHEMIC HEART DISEASE WITH ARTERIAL HYPERTENSION
Keywords:
ischemic heart disease, arterial hypertension, telmisartan, enalapril, phospholipids, lysophosphotidylcholine, phosphotidylcholine, syphingomyelin, phosphotidylserine, phosphatidylethanolamineAbstract
In the study phospholipids, cholesterol and its metabolites play a special role in of biological membranes. Disruption of the phospholipid content of biological membranes is one of the main factors of pathological processes, because phospholipids make up the largest part of the lipids of biological membranes, as well as platelet membranes. The study examined the effect of telmisartan on the clinical hemodynamics and platelet membrane phospholipids, cholesterol metabolism in patients with ischemic heart disease and arterial hypertension during 8 weeks of therapy.
References
2018 EOC/EOAG. Recommendations for treatment of patients with arterial hypertension // Russian Journal of Cardiology. 2018. Т. 23. № 12. pp. 143–228.
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, Alexander L, Estep K, Abate KH, Akinyemiju TF, Ali R, Alvis-Guzman N, Azzopardi P, Banerjee A, Bärnighausen T, Basu A, Bekele T, Bennett DA, Biadgilign S, Catalá-López F, Feigin VL, Fernandes JC, Fischer F, Gebru AA, Gona P, Gupta R, Hankey GJ, Jonas JB, Judd SE, Khang Y-H, Khosravi A, Kim YJ, Kimokoti RW, Kokubo Y, Kolte D, Lopez A, Lotufo PA, Malekzadeh R, Melaku YA, Mensah GA, Misganaw A, Mokdad AH, Moran AE, Nawaz H, Neal B, Ngalesoni FN, Ohkubo T, Pourmalek F, Rafay A, Kumar Rai R, Rojas-Rueda D, Sampson UK, Santos IS, Sawhney M, Schutte AE, Sepanlou SG, Shifa GT, Shiue I, Tedla BA, Thrift AG, Tonelli M, Truelsen T, Tsilimparis N, Ukwaja KN, Uthman OA, Vasankari T, Venketasubramanian N, Vlassov VV, Vos T, Westerman R, Yan LL, Yano Y, Yonemoto N, El Sayed Zaki M, Murray CJL. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990—2015. JAMA. 2017;317:165-182. https://doi.org/10.1001/jama.2016.19043
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-967. https://doi.org/10.1016/S0140-6736(15)01225-8
Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32:2285-2295. https://doi.org/10.1097/HJH.0000000000000378
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018 Sept;39(33);3021-3104. https://doi.org/10.1093/eurheart/ehy339
Chazova I.E, Zhernakova Y.V. on behalf of the experts. Clinical guidelines. Diagnostic and treatment of arterial hypertension. System Hypertensions. 2019;16(1):6-31. https://doi.org/10.26442/2075082X.2019.1.190179
Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26:1282-1289. https://doi.org/10.1097/HJH.0b013e328306ebe2
Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens. 2005;23:2113-2118. https://doi.org/10.1097/01.hjh.0000194114.12228.16
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. https://doi.org/10.1001/jama.2013.284427
Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O’Connor CM, O’Gara PT, Ogedegbe O, Oparil S, White WB. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American He art Association, American College of Cardiology, and American Society of Hypertension. J Am Soc Hypertens. 2015;9(6):453-498. https://doi.org/10.1016/j.jash.2015.03.002
Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
Aoyama T, Minatoguchi S. The effect of ARB on prevention of atherosclerosis. Nihon Rinsho. 2011;69:92-99.
Li YR. Cardiovascular diseases: from molecular pharmacology to evidence-based therapeutics. Hoboken: John Wiley & Sons; 2015.
Negro R. Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag. 2008;4:89-101.
Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35:2150-2160. https://doi.org/10.1097/HJH.0000000000001547
